Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,730 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: maeda y. Int J Hematol. 2024 Jun;119(6):677-685. doi: 10.1007/s12185-024-03738-8. Epub 2024 Mar 22. Int J Hematol. 2024. PMID: 38519820 Clinical Trial.
The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.
Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, Togitani K, Takimoto H, Hiramatsu Y, Kiguchi T, Yano T, Yamane H, Tabayashi T, Takeuchi M, Makita M, Sezaki N, Yamasuji Y, Sugiyama H, Tabuchi T, Kataoka I, Fujii N, Ishimaru F, Shinagawa K, Ikeda K, Hara M, Yoshino T, Tanimoto M; West-Japan Hematology and Oncology Group (West-JHOG). Nishimori H, et al. Among authors: maeda y. Int J Hematol. 2009 Apr;89(3):326-331. doi: 10.1007/s12185-009-0259-8. Epub 2009 Mar 27. Int J Hematol. 2009. PMID: 19326060
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.
Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T. Kurosawa S, et al. Among authors: maeda y. Haematologica. 2010 Nov;95(11):1857-64. doi: 10.3324/haematol.2010.027516. Epub 2010 Jul 15. Haematologica. 2010. PMID: 20634493 Free PMC article.
Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M. Ennishi D, et al. Among authors: maeda y. Blood. 2010 Dec 9;116(24):5119-25. doi: 10.1182/blood-2010-06-289231. Epub 2010 Sep 7. Blood. 2010. PMID: 20823454 Free article.
Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan.
Miura K, Takasaki H, Tsujimura H, Kanno M, Maeda Y, Tomita N, Takai K, Masaki Y, Takizawa J, Mori H, Terasaki Y, Yoshida T, Takeuchi J, Motomura S. Miura K, et al. Among authors: maeda y. Int J Hematol. 2011 May;93(5):684-686. doi: 10.1007/s12185-011-0845-4. Epub 2011 Apr 12. Int J Hematol. 2011. PMID: 21479980 No abstract available.
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Yamaguchi M, et al. Among authors: maeda y. J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990393 Clinical Trial.
Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, Fukushima N, Isobe Y, Takizawa J, Hasegawa Y, Kobayashi H, Okamura S, Kobayashi H, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Kawa K, Oshimi K, Suzuki R. Ito Y, et al. Among authors: maeda y. Clin Cancer Res. 2012 Aug 1;18(15):4183-90. doi: 10.1158/1078-0432.CCR-12-1064. Epub 2012 Jun 6. Clin Cancer Res. 2012. PMID: 22675173 Clinical Trial.
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.
Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, Igarashi T, Maeda Y, Fukuhara N, Ishida F, Niitsu N, Ohmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Ogura M. Aoki T, et al. Among authors: maeda y. Haematologica. 2014 Dec;99(12):1817-25. doi: 10.3324/haematol.2014.111203. Epub 2014 Sep 12. Haematologica. 2014. PMID: 25216682 Free PMC article.
α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice.
Uryu H, Hashimoto D, Kato K, Hayase E, Matsuoka S, Ogasawara R, Takahashi S, Maeda Y, Iwasaki H, Miyamoto T, Saijo S, Iwakura Y, Hill GR, Akashi K, Teshima T. Uryu H, et al. Among authors: maeda y. Blood. 2015 May 7;125(19):3014-23. doi: 10.1182/blood-2014-12-615781. Epub 2015 Mar 4. Blood. 2015. PMID: 25740827 Free article.
4,730 results